MedTrace Logo

Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

NCT06195137 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-01-08

No results posted yet for this study

Summary

The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.

Conditions

  • Caffeine
  • Burning Mouth Syndrome

Interventions

DIETARY_SUPPLEMENT

Caffeine

caffeine supplementation

DRUG

Alpha Lipoic Acid

600-800 mg ALA

Sponsors & Collaborators

  • Lu Jiang

    lead OTHER

Principal Investigators

  • Lu Jiang · Sichuan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2023-06-15
Completion
2023-06-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06195137 on ClinicalTrials.gov